阿瑪琳 AMRN 深 滬
等待開盤 05-20 09:30:00 美东时间
14.05
-0.010
-0.07%
華盛通- 最 高14.21
- 今 開14.00
- 成交量 3.16万股
- 最 低 13.80
- 昨 收 14.06
- 總市值 2.95亿
- 52周最高 20.90
- 市盈率 靜 --
- 換手率 0.15%
- 52周最低 11.42
- 委 比 34.29%
- 總股本 2096.91万
- 歷史最高 522.40
- 量 比 0.73
- 振 幅 2.92%
- 歷史最低 7.08
- 每 手 1
- 風險率 1.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Earnings Scheduled For April 29, 2026
Companies Reporting Before The Bell • Extreme Networks (NASDAQ:EXTR) is likely ...
04-29 19:11
Amarin Corp Q1 Sales $45.132M Beat $43.771M Estimate
Amarin Corp (NASDAQ:AMRN) reported quarterly sales of $45.132 million which beat the analyst consensus estimate of $43.771 million by 3.11 percent. This is a 7.41 percent increase over sales of $42.017 million the same
04-29 19:04
Amarin Highlights 2026 ACC/AHA Dyslipidemia Guideline Emphasizing CV Risk Management In Hypertriglyceridemia
Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, applauded the recommendation that the treatment of CV risk in patients with
03-18 20:33
Amarin shares are trading lower after the company reported a Q4 sales miss.
Amarin shares are trading lower after the company reported a Q4 sales miss.
02-26 01:24
Amarin Corp Earnings Report: Q4 Overview
Amarin Corp (NASDAQ:AMRN) announced its Q4 earnings on Wednesday, February 25, ...
02-25 20:04
Amarin Corp Q4 Adj. EPS $0.01 Beats $(0.56) Estimate, Sales $49.219M Miss $50.619M Estimate
Amarin Corp (NASDAQ:AMRN) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.56) by 101.79 percent. This is a 150 percent increase over losses of $(0.02) per share from the
02-25 20:03
Earnings Scheduled For February 25, 2026
Companies Reporting Before The Bell • Clear Secure (NYSE:YOU) is expected to re...
02-25 19:11
Amarin Reports $217M Revenue and $303M Cash in Preliminary Full-Year 2025 Results
Amarin Corporation plc (NASDAQ:AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced select preliminary unaudited 2025 financial highlights, provided a summary of key 2025
01-08 20:14
Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities
Amarin Corporation plc reported strong financial performance in 2025, achieving positive cash flow in Q4 and ending the year with a cash balance of $303 million. They sustained market leadership in the U.S. for VASCEPA, with over 50% of IPE prescriptions, and expanded their presence in Europe through a partnership with Recordati, commercializing VAZKEPA in 59 countries. The company also secured regulatory approvals in South Korea and Singapore. W...
01-08 12:00
Amarin To Present New Data Highlighting VASCEPA's Cardiovascular Benefits And EPA's Anti-Inflammatory, Antioxidant Mechanisms At AHA 2025
Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced it will be presenting new findings at the American Heart Association's Scientific Sessions 2025 scheduled for November 7-10 in New Orleans, Louisiana.
2025-11-03 21:41
